Helixgate

Helixgate

Uncategorized

Pfizer is a 2029 story but Q126 lays foundation for growth

Published

on

A legal settlement has put wind behind Pfizer’s sales into 2029—at which point key obesity moves will take the helm.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

STAT+: A new attack on AMA’s billing codes

You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays.

Brain Reid, who writes a newsletter on drug pricing policies, wrote “health care [sic]” in his Friday edition. I feel like a huge dork for laughing at that “sic” notation. Share your thoughts on the AP’s new compound noun dictum here, and send news tips to John.Wilkerson@statnews.com or John_Wilkerson.07 on Signal.

CPT codes are the new front in fraud allegations

House oversight committee Chair James Comer (R-Ky.) is taking aim at the American Medical Association, linking the biggest doctor lobby’s billing codes to potential fraud, waste, and abuse.

Continue to STAT+ to read the full story…

Read More

Published

on

You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays.

Brain Reid, who writes a newsletter on drug pricing policies, wrote “health care [sic]” in his Friday edition. I feel like a huge dork for laughing at that “sic” notation. Share your thoughts on the AP’s new compound noun dictum here, and send news tips to John.Wilkerson@statnews.com or John_Wilkerson.07 on Signal.

CPT codes are the new front in fraud allegations

House oversight committee Chair James Comer (R-Ky.) is taking aim at the American Medical Association, linking the biggest doctor lobby’s billing codes to potential fraud, waste, and abuse.

Continue to STAT+ to read the full story…

Read More

Continue Reading

Uncategorized

BioNTech to scale down manufacturing, over 1,800 jobs on the line

Published

on

BioNTech is making big cuts to its manufacturing footprint.

The German company said in its first-quarter earnings release that up to 1,860 manufacturing staff could be impacted by its planned downsizing …

Continue Reading

Uncategorized

Viridian data lift prospects for thyroid eye disease drug

Whereas earlier Phase 3 results disappointed Wall Street, new findings in people with “chronic” disease were viewed by analysts as much more competitive with Amgen’s Tepezza.

Read More

Published

on

Whereas earlier Phase 3 results disappointed Wall Street, new findings in people with “chronic” disease were viewed by analysts as much more competitive with Amgen’s Tepezza.

Read More

Continue Reading
Advertisement

Trending